{"id":71710,"date":"2026-08-05T13:39:58","date_gmt":"2026-08-05T05:39:58","guid":{"rendered":"https:\/\/flcube.com\/?p=71710"},"modified":"2026-08-05T13:39:59","modified_gmt":"2026-08-05T05:39:59","slug":"alphamab-oncologys-anbenitamab-nda-accepted-by-china-nmpa-for-her2-breast-cancer-neoadjuvant-treatment-granted-priority-review","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71710","title":{"rendered":"Alphamab Oncology&#8217;s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Alphamab Oncology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/9966:HKG\">HKG: 9966<\/a>) announced that the <strong>New Drug Application (NDA)<\/strong> for <strong>Anbenitamab<\/strong> (trade name: Ennituo, R&amp;D code: KN026), co-developed with <strong>Shanghai JMT-Bio Technology Co., Ltd.<\/strong> (JMT-Bio), a subsidiary of <strong>CSPC Pharmaceutical Group Limited<\/strong> (1093.HK), in combination with <strong>docetaxel (albumin-bound) for injection (HB1801)<\/strong> as neoadjuvant treatment for <strong>human epidermal growth factor receptor 2-positive (HER2+) early or locally advanced breast cancer<\/strong>, has been <strong>accepted by China&#8217;s National Medical Products Administration (NMPA)<\/strong> and <strong>included in the priority review and approval procedure<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Anbenitamab (Ennituo) + HB1801 combination<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Neoadjuvant treatment for HER2+ early or locally advanced breast cancer<\/td><\/tr><tr><td><strong>Review Status<\/strong><\/td><td>Priority review and approval procedure<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>May 2026 for HER2+ gastric cancer\/gastroesophageal junction cancer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule<\/strong>: Anti-HER2 bispecific antibody<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Simultaneously binds two non-overlapping epitopes of HER2, resulting in comprehensive HER2 signal blockade<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: Novel bispecific approach offering enhanced target engagement compared to single-epitope antibodies<\/li>\n\n\n\n<li><strong>Development Partnership<\/strong>: Co-developed with JMT-Bio (CSPC Pharmaceutical Group subsidiary)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-iii-kn026-004-neo-healer-trial\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase III KN026-004\/Neo-Healer Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Anbenitamab + HB1801<\/th><th>Standard Therapy (Trastuzumab + Pertuzumab + Docetaxel)<\/th><th>Statistical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Pathological Complete Response (tpCR)<\/strong><\/td><td>62.4% (95% CI: 56.20\u201368.23)<\/td><td>Not disclosed (comparator arm)<\/td><td>One-sided P=0.0036<\/td><\/tr><tr><td><strong>Clinical Benefit<\/strong><\/td><td>Superior efficacy with statistical and clinical value<\/td><td>Current standard of care<\/td><td>Established superiority<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Manageable overall safety profile<\/td><td>Comparable to established regimens<\/td><td>Favorable risk-benefit ratio<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The pivotal phase III study enrolled patients with HER2+ early or locally advanced breast cancer and demonstrated that Anbenitamab in combination with HB1801, with or without Carboplatin, significantly improved tpCR compared to the current standard therapy.<\/p>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HER2+ Breast Cancer Market<\/strong>: Represents approximately 15\u201320% of all breast cancer cases globally, with significant unmet need for more effective neoadjuvant therapies<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Dual HER2 blockade with trastuzumab and pertuzumab plus chemotherapy<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: Anbenitamab&#8217;s bispecific design may offer superior efficacy through enhanced HER2 pathway inhibition<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Building on recent approval in gastric cancer indication, expanding into the larger breast cancer market<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Diversification<\/strong>: Second major indication following gastric cancer approval in May 2026<\/li>\n\n\n\n<li><strong>Partnership Validation<\/strong>: Successful collaboration model with CSPC Pharmaceutical Group through JMT-Bio subsidiary<\/li>\n\n\n\n<li><strong>Regulatory Strategy<\/strong>: Leveraging priority review pathway for accelerated market access<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Strong phase III data may support future international regulatory submissions<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical trial results, and commercial potential. Actual outcomes may differ due to risks including final regulatory decisions, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080401577_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026080401577_c.\"><\/object><a id=\"wp-block-file--media-442fcb72-0f93-4ce2-9161-fd6b7e3eda2f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080401577_c.pdf\">2026080401577_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026080401577_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-442fcb72-0f93-4ce2-9161-fd6b7e3eda2f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[187,83,854,28],"class_list":["post-71710","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-alphamab-oncology","tag-her2","tag-hkg-9966","tag-multi-specific-antibodies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alphamab Oncology&#039;s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name: Ennituo, R&amp;D code: KN026), co-developed with Shanghai JMT-Bio Technology Co., Ltd. (JMT-Bio), a subsidiary of CSPC Pharmaceutical Group Limited (1093.HK), in combination with docetaxel (albumin-bound) for injection (HB1801) as neoadjuvant treatment for human epidermal growth factor receptor 2-positive (HER2+) early or locally advanced breast cancer, has been accepted by China&#039;s National Medical Products Administration (NMPA) and included in the priority review and approval procedure.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71710\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alphamab Oncology&#039;s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review\" \/>\n<meta property=\"og:description\" content=\"Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name: Ennituo, R&amp;D code: KN026), co-developed with Shanghai JMT-Bio Technology Co., Ltd. (JMT-Bio), a subsidiary of CSPC Pharmaceutical Group Limited (1093.HK), in combination with docetaxel (albumin-bound) for injection (HB1801) as neoadjuvant treatment for human epidermal growth factor receptor 2-positive (HER2+) early or locally advanced breast cancer, has been accepted by China&#039;s National Medical Products Administration (NMPA) and included in the priority review and approval procedure.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71710\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T05:39:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-05T05:39:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71710#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71710\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alphamab Oncology&#8217;s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review\",\"datePublished\":\"2026-08-05T05:39:58+00:00\",\"dateModified\":\"2026-08-05T05:39:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71710\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Alphamab Oncology\",\"HER2\",\"HKG: 9966\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71710#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71710\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71710\",\"name\":\"Alphamab Oncology's Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-05T05:39:58+00:00\",\"dateModified\":\"2026-08-05T05:39:59+00:00\",\"description\":\"Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name: Ennituo, R&D code: KN026), co-developed with Shanghai JMT-Bio Technology Co., Ltd. (JMT-Bio), a subsidiary of CSPC Pharmaceutical Group Limited (1093.HK), in combination with docetaxel (albumin-bound) for injection (HB1801) as neoadjuvant treatment for human epidermal growth factor receptor 2-positive (HER2+) early or locally advanced breast cancer, has been accepted by China's National Medical Products Administration (NMPA) and included in the priority review and approval procedure.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71710#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71710\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71710#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alphamab Oncology&#8217;s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alphamab Oncology's Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review - Insight, China&#039;s Pharmaceutical Industry","description":"Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name: Ennituo, R&D code: KN026), co-developed with Shanghai JMT-Bio Technology Co., Ltd. (JMT-Bio), a subsidiary of CSPC Pharmaceutical Group Limited (1093.HK), in combination with docetaxel (albumin-bound) for injection (HB1801) as neoadjuvant treatment for human epidermal growth factor receptor 2-positive (HER2+) early or locally advanced breast cancer, has been accepted by China's National Medical Products Administration (NMPA) and included in the priority review and approval procedure.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71710","og_locale":"en_US","og_type":"article","og_title":"Alphamab Oncology's Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review","og_description":"Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name: Ennituo, R&D code: KN026), co-developed with Shanghai JMT-Bio Technology Co., Ltd. (JMT-Bio), a subsidiary of CSPC Pharmaceutical Group Limited (1093.HK), in combination with docetaxel (albumin-bound) for injection (HB1801) as neoadjuvant treatment for human epidermal growth factor receptor 2-positive (HER2+) early or locally advanced breast cancer, has been accepted by China's National Medical Products Administration (NMPA) and included in the priority review and approval procedure.","og_url":"https:\/\/flcube.com\/?p=71710","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-05T05:39:58+00:00","article_modified_time":"2026-08-05T05:39:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71710#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71710"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alphamab Oncology&#8217;s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review","datePublished":"2026-08-05T05:39:58+00:00","dateModified":"2026-08-05T05:39:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71710"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Alphamab Oncology","HER2","HKG: 9966","Multi-specific antibodies"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71710#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71710","url":"https:\/\/flcube.com\/?p=71710","name":"Alphamab Oncology's Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-05T05:39:58+00:00","dateModified":"2026-08-05T05:39:59+00:00","description":"Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name: Ennituo, R&D code: KN026), co-developed with Shanghai JMT-Bio Technology Co., Ltd. (JMT-Bio), a subsidiary of CSPC Pharmaceutical Group Limited (1093.HK), in combination with docetaxel (albumin-bound) for injection (HB1801) as neoadjuvant treatment for human epidermal growth factor receptor 2-positive (HER2+) early or locally advanced breast cancer, has been accepted by China's National Medical Products Administration (NMPA) and included in the priority review and approval procedure.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71710#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71710"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71710#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alphamab Oncology&#8217;s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71710"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71710\/revisions"}],"predecessor-version":[{"id":71714,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71710\/revisions\/71714"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}